Drugs in ATC Class P02CE

Up to Top Level ATC Classes

Up to P - Antiparasitic products, insecticides and repellents

Up to P02 - ANTHELMINTICS

Up to P02C - ANTINEMATODAL AGENTS

Drugs in ATC Class: P02CE - Imidazothiazole derivatives

Tradename	Generic Name
ERGAMISOL	levamisole hydrochloride

P02CE Market Analysis and Financial Projection

The ATC class P02CE (imidazothiazole derivatives) encompasses antiparasitic drugs, with levamisole being the primary example (ATC code P02CE01). This analysis examines market trends and patent activity in this therapeutic category.

---

Market Dynamics

Global Growth Trends

• The imidazoline derivative inhibitor market (closely related to imidazothiazoles) was valued at $1.29B in 2024, projected to reach $2.20B by 2034 at a 5.5% CAGR[3][18]. Growth is fueled by:
  • Rising demand for targeted therapies in chronic conditions like hypertension and neurological disorders.
  • Advancements in drug discovery, particularly with phosphonic acid derivatives, which are outpacing alkyl benzothiazoles in growth due to novel applications[3].
  • Expansion in Asia-Pacific markets driven by industrialization and healthcare investments in China and India[3][7].

Regional Insights

• North America leads with ~40% market share, attributed to robust R&D infrastructure and high adoption of advanced therapies[7][18].
• Baltic Region: Cardiovascular drugs dominate, but P02CE-class drugs like levamisole maintain niche use (~0.01 DDD/1000 inhabitants/day in Lithuania and Latvia)[1][5].

Key Therapeutic Segments

• Alkyl benzothiazoles: Hold the largest market share due to efficacy in hypertension management[3].
• Antiparasitics: Levamisole remains a critical anthelmintic, though its consumption is dwarfed by broader ATC groups (e.g., cardiovascular drugs account for 15–30% of market turnover in Estonia and Lithuania)[1][5].

---

Patent Landscape

Core Innovations

• Combination formulations: Patents like WO 2015086504 A1 cover levamisole-macrocyclic lactone injectables for veterinary use, addressing parasite resistance[12]. A 2020 Australian court upheld Intervet’s patent (AU 2011268899) for an oil-based suspension with 10–35% levamisole, deeming it non-obvious despite prior art[12].
• Therapeutic expansions:
  • Cancer: US 8,916,711 B2 claims imidazothiazole-chalcone derivatives as anticancer agents[10].
  • Immunomodulation: WO 2008156866A1 targets sirtuin modulation for metabolic disorders[10].

Legal Challenges

• Patent disputes often hinge on formulation novelty. For example, Intervet successfully defended their injectable levamisole formulation by demonstrating unexpected stability and efficacy compared to prior solutions[12].

---

Future Outlook

• Personalized medicine: Emerging focus on genetic-tailored therapies using imidazothiazole derivatives for neurological and metabolic disorders[18].
• Phosphonic acid derivatives: Expected to drive market growth through enhanced pharmacokinetic profiles[3].
• Regulatory shifts: Levamisole’s inclusion in WHO Essential Medicines Lists underscores its therapeutic value, though competition from newer antiparasitics may impact long-term demand[4][8].

---

Highlight:

"The formulation of levamisole as a particulate in oil was a substantial departure from prior art, solving longstanding stability challenges."
— Boehringer Ingelheim Animal Health USA Inc. v Intervet International B.V. [12]

This sector’s evolution hinges on balancing innovation in niche applications (e.g., veterinary anthelmintics) with expanding into broader therapeutic areas through derivative development.

References

1. https://vvkt.lrv.lt/media/viesa/saugykla/2023/9/09vLW9zMlcw.pdf
2. https://go.drugbank.com/drugs/DB00848
3. https://www.polarismarketresearch.com/industry-analysis/imidazoline-derivative-inhibitor-market
4. https://list.essentialmeds.org/files/trs/PXjEBzgbrMCpEHRGYEuB56NGdqGSBShvFrSzvRTL.pdf
5. https://www.zva.gov.lv/sites/default/files/2018-05/zva-zstat-2017.pdf
6. https://prediction.charite.de/subpages/tree.php
7. https://www.verifiedmarketresearch.com/product/imidazoline-derivative-inhibitor-market/
8. https://list.essentialmeds.org/files/trs/uM2drf3qopwZIceChtyH0tqRGk7c86aLZRZYZimX.pdf
9. https://patents.google.com/patent/US7449012B2/en
10. https://ouci.dntb.gov.ua/works/lm3V8ZO7/
11. https://carsbits.com/p02ce-cylinder-2-fuel-injector-offset-learning-at-min-limit-causes-symptoms-and-solutions
12. https://www.spruson.com/intervet-parries-a-challenge-to-its-combination-injectable-anthelmintic-formulation-patent-application/
13. https://www.rhsupplies.org/uploads/tx_rhscpublications/WHO_selection%20&%20use%20of%20essential%20medicines_Technical%20Report%20Series%20920_misoprostol_2003.pdf
14. https://patents.google.com/patent/EP2103619A1/en
15. https://atcddd.fhi.no/filearchive/publications/2025_guidelines__final_web.pdf
16. https://www.pharmacompass.com/chemistry-chemical-name/decaris
17. https://patents.google.com/patent/WO1993015716A1/en
18. https://www.globenewswire.com/news-release/2024/12/12/2995987/0/en/Imidazoline-Derivative-Inhibitor-Market-Share-to-Rise-At-5-5-CAGR-To-Surpass-USD-2-20-Billion-by-2034-PMR.html